Comparing the novel method of assessing PrEP adherence/exposure using hair samples to other pharmacologic and traditional measures.

ABSTRACT:

Objective

The efficacy of pre-exposure prophylaxis (PrEP) in HIV will diminish with poor adherence; pharmacologic measures of drug exposure have proven critical to PrEP trial interpretation. We assessed drug exposure in hair against other pharmacologic and more routinely used measures to assess pill-taking.

Design

Participants were randomized to placebo, daily PrEP, or intermittent PrEP to evaluate safety and tolerability of daily versus intermittent tenofovir/emtricitabine (TFV/FTC) in 2 phase II PrEP clinical trials conducted in Africa. Different measures of drug exposure, including self-report, medication event monitoring system (MEMS)-caps openings, and TFV/FTC levels in hair and other biomatrices were compared.

Methods

At weeks 8 and 16, self-reported pill-taking

SUBMITTER: Baxi SM 

PROVIDER: S-EPMC4262724 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature